Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating

Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ALMS stock, giving a Buy rating on March 3.

Thomas Smith’s rating is based on several promising developments in Alumis Inc.’s clinical programs. The company has shown positive progress with its lead program, ESK-001, a TYK2 inhibitor for psoriasis. The timing for the release of Phase 3 trial data has been narrowed to the first quarter of 2026, indicating strong enrollment trends and effective clinical execution. Additionally, the acceptance of long-term data for ESK-001 as a late-breaking presentation at a major dermatology conference suggests significant interest and confidence in its efficacy.
Furthermore, Alumis Inc.’s CNS-penetrant TYK2 inhibitor, A-005, has demonstrated the ability to cross the blood-brain barrier effectively, with favorable pharmacokinetics and no serious adverse events reported. This reinforces the potential of A-005 to address inflammation in the central nervous system, a challenging therapeutic area. Overall, the compelling clinical profiles of both ESK-001 and A-005 support the Buy rating, as they offer potential best-in-class treatments in their respective areas.

In another report released on March 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $19.00 price target.

Disclaimer & DisclosureReport an Issue